Press release Communiqué de presse

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter

Press release Communiqué de presse


March 17, 2008 17 March, 2008

Sernova Corp. Grants Stock Options


Sernova Corp. (the "Company") has granted incentive stock options to directors, officers and employees to purchase up to 375,000 common shares at $0.30 per share for a period of 5 years expiring March 14, 2013.

About Sernova

Sernova Corp. is a Canadian based, health sciences company focused on commercializing medical technologies and currently working to cure insulin dependent diabetes using its patented Sertolin technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. Over $100 billion per year is spent in the US on treating diabetes and its complications, and worldwide expenditures on insulin is estimated to be $25 billion annually.

ON BEHALF OF THE BOARD

"Justin Leushner"

Justin Leushner, President and CEO

For further information contact: Phil Morehouse Sernova Corp. TEL: (888) 318-7062 FAX: (250) 868-8493 info@sernovacorp.com www.sernovacorp.com

THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.